In summary, brain metastatic as conventional melanoma cell lines responded to METi, suggesting that targeting MET signaling might be a promising tool for the treatment of non-BRAFV600 and BRAFV600 mutated MBM that acquired resistance to BRAFi or for combinatorial of METi and ICi in NRAS mutated tumors and all MET expressing cellular subsets including BRAFi refractory NGFR+ cells. This evidence concerns the gene NRAS and melanoma.